Please assess the completion status of the following clinical trial:

Trial Title: Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Agreement to participate in study;~2. A history of TBI resulting from, but not limited to, any of the following: contact sports, accidents, violence, or military combat;~3. Age 18 or older;~4. No significant cerebrovascular disease;~5. Adequate visual and auditory acuity to allow neuropsychological testing;~6. Screening laboratory tests without significant abnormalities that might interfere with the study.~Exclusion Criteria:~1. Preexisting major neurological or other physical illness that could confound results (e.g., multiple sclerosis, diabetes, cancer);~2. History of myocardial infarction within the previous year or unstable cardiac disease.~3. Uncontrolled hypertension (systolic blood pressure \> 170 or diastolic blood pressure \> 100),~4. History of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer.~5. Such current major psychiatric disorders as mania within the previous two years.~6. Participants taking drugs that are known to affect \[F-18\]FDDNP-PET binding (e.g., ibuprofen, naproxen) were asked to stop taking medication one week prior to PET scan or excluded from the study.~7. Use of any investigational drugs within the previous month, depending on drug half-life.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Suspected CTE (Type: None): A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, \[F-18\]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).

Based on this trial design, predict the completion outcome and termination type (if applicable).